Guo F, Ji X, Xiong C, Sun H, Liang Z, Yan-Do R
Nat Commun. 2024; 15(1):9985.
PMID: 39562763
PMC: 11576956.
DOI: 10.1038/s41467-024-53419-7.
Tan L, Ni Y, Huang Z, Yan J, Wu M, Zhang Z
Future Oncol. 2024; 20(26):1943-1960.
PMID: 39129672
PMC: 11498025.
DOI: 10.1080/14796694.2024.2373680.
Weidle U, Birzele F
Cancer Genomics Proteomics. 2024; 21(3):213-237.
PMID: 38670587
PMC: 11059596.
DOI: 10.21873/cgp.20442.
Neuhaus F, Lieber S, Shinkevich V, Steitz A, Raifer H, Roth K
Clin Transl Med. 2024; 14(4):e1604.
PMID: 38566518
PMC: 10988119.
DOI: 10.1002/ctm2.1604.
Constantinescu D, Sorop A, Ghionescu A, Lixandru D, Herlea V, Bacalbasa N
Front Pharmacol. 2024; 15:1363142.
PMID: 38510654
PMC: 10953505.
DOI: 10.3389/fphar.2024.1363142.
The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor H, Asare-Werehene M, Pereira S, Satyamoorthy K, Tsang B
J Ovarian Res. 2024; 17(1):15.
PMID: 38216951
PMC: 10785480.
DOI: 10.1186/s13048-023-01332-w.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho G, Vandenberg C, Lim R, Christie E, Garsed D, Lieschke E
Ther Adv Med Oncol. 2023; 15:17588359231208674.
PMID: 38028140
PMC: 10666702.
DOI: 10.1177/17588359231208674.
Pain nursing for gynecologic cancer patients.
Wu W, He X, Li S, Jin M, Ni Y
Front Oncol. 2023; 13:1205553.
PMID: 37564934
PMC: 10410261.
DOI: 10.3389/fonc.2023.1205553.
Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.
Adzibolosu N, Alvero A, Ali-Fehmi R, Gogoi R, Corey L, Tedja R
Front Immunol. 2023; 14:1204148.
PMID: 37435088
PMC: 10331425.
DOI: 10.3389/fimmu.2023.1204148.
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A, Cainap S, Havasi A, Cainap C
Medicina (Kaunas). 2023; 59(3).
PMID: 36984544
PMC: 10057458.
DOI: 10.3390/medicina59030544.
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses.
Kampan N, Kartikasari A, Deceneux C, Madondo M, McNally O, Flanagan K
Cancers (Basel). 2023; 15(3).
PMID: 36765633
PMC: 9913655.
DOI: 10.3390/cancers15030667.
Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
Yang Q, Bae G, Nadiradze G, Castagna A, Berezhnoy G, Zizmare L
J Transl Med. 2022; 20(1):581.
PMID: 36503580
PMC: 9743551.
DOI: 10.1186/s12967-022-03763-3.
Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.
Wang Y, Zhang L, Bai Y, Wang L, Ma X
Front Immunol. 2022; 13:1036298.
PMID: 36341388
PMC: 9630909.
DOI: 10.3389/fimmu.2022.1036298.
Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer.
Hua T, Zhang X, Wang W, Tian Y, Chen S
Front Genet. 2022; 13:901424.
PMID: 36246624
PMC: 9557066.
DOI: 10.3389/fgene.2022.901424.
TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse.
Holmberg R, Robinson M, Gilbert S, Lujano-Olazaba O, A Waters J, Kogan E
Mol Cancer Res. 2022; 21(2):170-186.
PMID: 36214671
PMC: 9890141.
DOI: 10.1158/1541-7786.MCR-22-0486.
Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer.
Mendes R, Graca G, Silva F, Guerreiro A, Gomes-Alves P, Serpa J
Cancers (Basel). 2022; 14(18).
PMID: 36139619
PMC: 9496731.
DOI: 10.3390/cancers14184460.
Homo and Heterotypic Cellular Cross-Talk in Epithelial Ovarian Cancer Impart Pro-Tumorigenic Properties through Differential Activation of the Notch3 Pathway.
Mukherjee S, Sakpal A, Mehrotra M, Phadte P, Rekhi B, Ray P
Cancers (Basel). 2022; 14(14).
PMID: 35884426
PMC: 9319742.
DOI: 10.3390/cancers14143365.
Human monocytes differentiate into tumor-associated macrophages upon SKOV3 cells coculture and/or lysophosphatidic acid stimulation.
Feng Y, Xiao M, Cao G, Liu H, Li Y, Wang S
J Inflamm (Lond). 2022; 19(1):11.
PMID: 35842650
PMC: 9288080.
DOI: 10.1186/s12950-022-00307-w.
Enhancing the anti-ovarian cancer activity of quercetin using a self-assembling micelle and thermosensitive hydrogel drug delivery system.
Xu G, Li B, Wang T, Wan J, Zhang Y, Huang J
RSC Adv. 2022; 8(38):21229-21242.
PMID: 35539921
PMC: 9080896.
DOI: 10.1039/c8ra03274b.
Multi-staged gene expression profiling reveals potential genes and the critical pathways in kidney cancer.
Khouja H, Ashankyty I, Bajrai L, Praveen Kumar P, Kamal M, Firoz A
Sci Rep. 2022; 12(1):7240.
PMID: 35508649
PMC: 9065671.
DOI: 10.1038/s41598-022-11143-6.